Chronic hepatitis B: what should be the goal for new therapies? - Test2 - elhamkhani - TriplyDB

Chronic hepatitis B: what should be the goal for new therapies?

Chronic hepatitis B: what should be the goal for new therapies?

http://www.wikidata.org/entity/Q36769986

about

Hepatitis B virus and its sexually transmitted infection - an update.Current hepatitis B treatment guidelines and future research directions.Hepatitis B virus replication is blocked by a 2-hydroxyisoquinoline-1,3(2H,4H)-dione (HID) inhibitor of the viral ribonuclease H activity Hepatitis B virus: new therapeutic perspectives.Viral hepatitis among drug users in methadone maintenance: associated factors, vaccination outcomes, and interventions Engineered external guide sequences are highly effective in inhibiting gene expression and replication of hepatitis B virus in cultured cells.STING agonists induce an innate antiviral immune response against hepatitis B virus.Hydroxylated tropolones inhibit hepatitis B virus replication by blocking viral ribonuclease H activity.Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine.The hepatitis B virus ribonuclease H as a drug target How further suppression of virus replication could improve current HBV treatment.Mutation Changes in the preC/Core Promoter in HBeAg-Positive Patients With Chronic Hepatitis B During Interferon Therapy.Hepatitis B Virus Polymerase Localizes to the Mitochondria, and Its Terminal Protein Domain Contains the Mitochondrial Targeting Signal.HBsAg and HBeAg in the prediction of a clinical response to peginterferon α-2b therapy in Chinese HBeAg-positive patients Evolving New Strategies for the Medical Management of Chronic Hepatitis B Virus Infection.Treatment of Hepatitis B: A Concise Review.Chronic hepatitis B: A wave of new therapies on the horizon.Current treatment of hepatitis B virus infections.Metabolism and function of hepatitis B virus cccDNA: Implications for the development of cccDNA-targeting antiviral therapeutics.Therapeutic strategies for a functional cure of chronic hepatitis B virus infection.New therapies for chronic hepatitis B.Synergistic Interactions between Hepatitis B Virus RNase H Antagonists and Other Inhibitors.Establishment of an inducible HBV stable cell line that expresses cccDNA-dependent epitope-tagged HBeAg for screening of cccDNA modulators.The current status and future directions of hepatitis B antiviral drug discovery.Review article: novel therapies for hepatitis B virus cure - advances and perspectives.Toward Elimination of Hepatitis B Virus Using Novel Drugs, Approaches, and Combined Modalities Hepatitis B virus genetic diversity has minimal impact on sensitivity of the viral ribonuclease H to inhibitors.Purification and enzymatic characterization of the hepatitis B virus ribonuclease H, a new target for antiviral inhibitors.Epigenetic Regulation of Hepatitis B Virus Covalently Closed Circular DNA: Implications for Epigenetic Therapy against Chronic Hepatitis B.Isolation and functional characterization of hepatitis B virus-specific T-cell receptors as new tools for experimental and clinical use.Hepatitis B surface antigen loss and sustained viral suppression in Asian chronic hepatitis B patients: A community-based real-world study.Discovery and Mechanistic Study of Benzamide Derivatives That Modulate Hepatitis B Virus Capsid Assembly.CRISPR/Cas9 nickase-mediated disruption of hepatitis B virus open reading frame S and X.New horizon for radical cure of chronic hepatitis B virus infection.Characterization of novel hepadnaviral RNA species accumulated in hepatoma cells treated with viral DNA polymerase inhibitors A potent human neutralizing antibody Fc-dependently reduces established HBV infections HBeAg-negative chronic hepatitis patients should be monitored more strictly: a cross-sectional retrospective study on antiviral treatment-naïve patients.Advancing the regulatory path on hepatitis B virus treatment and curative research: a stakeholders consultation.Immunotherapy for Chronic Hepatitis B Virus Infection.The role of host DNA ligases in hepadnavirus covalently closed circular DNA formation.

P2860

Q30235028-4D511521-495A-44CE-A957-4F8021A08DEE Q30487002-9BDBEF9B-2592-43EE-953F-4175B5BF616C Q33911464-65278693-2131-4045-ABB2-A788CCB5763F Q34507250-0AB0C4A9-0D79-428D-BC80-AFC7055A4ECC Q34765548-4F4CC163-914A-4E35-B401-108B52CB4017 Q34775644-3DB6BA51-FF87-4F0E-A561-A57A994F97C2 Q35105855-9A5B6734-808C-4DBE-A662-4768378D542F Q35105877-C8CDF313-5AF9-4336-BC89-99287BA9B166 Q35473087-429DBE85-89B6-4E3D-AD03-D295F7CBAF6F Q35582561-01D207E1-668D-4895-A5CF-998BD89A1682 Q35622347-3ABAF088-5EEA-4259-A05F-98BE160EFC93 Q36566914-AB4B6F1E-C091-44BC-A312-703C54914063 Q37253020-A3D6963E-8EB5-4F7E-999A-9DE855221AD1 Q37374481-BD6E43C5-4A32-426C-9441-3F900B887FC7 Q37540212-E56D8C38-753D-45F2-AFCD-FFE21D933BE9 Q37620340-0F3CA2EF-38C2-481C-BEEB-87B95169E1DB Q38538107-B553EDF4-06F3-4CFB-BC4E-98796B2AFDFE Q38553056-A3923CED-54D0-4B6A-BC3B-7C12977CE4C8 Q38566445-57E6B57C-F837-4C91-AB40-F3003B3B7AF2 Q38636988-491F99CD-4A49-44DC-B475-90AFB82D3940 Q38725759-B60C9D1B-5329-413F-8995-EF26140716A1 Q38726548-BC2EC67F-761A-4860-8BB7-23C46C659713 Q38770516-9BA7A1E9-EB6C-4789-AF96-988EE73EA777 Q38802098-65E06222-B3D5-4608-8737-C29CAD8C77F6 Q38865511-656BFEFB-0524-4853-A358-0940D1A07EDC Q38980907-C6B37D93-608F-4BAD-BF0D-D4F7A7D6C559 Q39332246-24D84B10-2427-42A8-986B-F3D1CAEE3AA4 Q39671295-E49D582D-8397-43C7-9BA8-4D4031113B0F Q40073818-FC1A268F-FCE9-4771-B7DD-472B26CA6771 Q40089302-D2F51B6C-D5AC-4887-B204-4F2A0E9F8C4B Q40172735-C680F7EB-24B3-461E-AAB4-EBA64C8B8FE9 Q40178518-5E2BF332-DEBD-440C-8FAA-81552D5A9AC4 Q40580426-28C54C58-1373-4459-8332-05CF0ABA35A4 Q40593364-B92E305A-5D82-43A8-A8FE-0C6275D47107 Q40798098-F242443E-A27F-4897-8A3D-FE3EAAB3B386 Q41671765-44F13BE0-1948-4BD3-A298-48BDBD3A36CF Q41744323-CC946736-E91C-4560-879A-C98FC18D2436 Q42318295-677297C2-BC65-4976-BE0F-EF13C3334F57 Q47556416-3028AA80-CCE5-42B6-BF0E-C97752D5F833 Q47559691-2286F903-D17D-4006-8450-7DC6A389EBD4

P2860

Chronic hepatitis B: what should be the goal for new therapies?

http://www.wikidata.org/entity/Q36769986

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Chronic hepatitis B: what should be the goal for new therapies?

@ast

Chronic hepatitis B: what should be the goal for new therapies?

@en

type

label

Chronic hepatitis B: what should be the goal for new therapies?

@ast

Chronic hepatitis B: what should be the goal for new therapies?

@en

prefLabel

Chronic hepatitis B: what should be the goal for new therapies?

@ast

Chronic hepatitis B: what should be the goal for new therapies?

@en

P1433

Q36769986-B437CF05-BA52-4DE6-B5C3-18B9D846FCF9

P1476

Q36769986-AD4E008E-B678-49DD-8F74-3538752B4084

P2093

Q36769986-3DBB5AA6-B30A-4E98-9C99-3A7234BDC42D

Q36769986-47A8812C-FB31-4F3E-8418-61D7334ED86B

Q36769986-645AAF92-50F7-4C8E-A1CD-F023283691A6

Q36769986-CB7337C4-AD46-4E1B-8A37-4D7BEA5AE8F8

Q36769986-E3D1697B-4D4D-4071-98FC-C694AACC082C

Q36769986-F9AF6B0C-B474-46BB-BED7-F50AD9B53298

Q36769986-FC0EBD91-8D30-4F62-8649-01C86FDFDBB6

P2860

Q36769986-0047FC47-C627-4121-9662-DA17D4BAFEA7

Q36769986-01EE1484-AA42-4A36-B2AF-73AA3DD09B93

Q36769986-02220B87-2C16-4F88-A2C4-E61FEF5BC112

Q36769986-047F9778-E85A-46DF-B6C6-AD9C31898EF5

Q36769986-076B994C-E769-48FA-9DD6-51B5E87769E0

Q36769986-0E02A2F3-A77D-4A27-B250-58BCB0F9848C

Q36769986-1349D051-7814-4BB9-8CDC-008E963F3A06

Q36769986-157CFE16-855B-43CF-8E5C-8215F81DA037

Q36769986-1E298E43-7E5E-4038-A7F4-FBDCE2E1A5BC

Q36769986-221588FC-094F-40F2-BEEF-0697DA04AFF8

P304

Q36769986-C9E4773C-F31E-4607-8857-E6F8796E4C85

P31

Q36769986-414C900B-4895-4AF3-8903-1E10559DE73F

P356

Q36769986-2149B094-AE1B-45B7-A160-B04407AD3976

P433

Q36769986-EBC21D70-22B5-4231-8AE1-67A70048A7B4

P478

Q36769986-323317ED-688C-4FB3-8276-30CD7C218753

P577

Q36769986-C3B8EEF7-8868-4C63-BDAB-D6054279674B

P698

Q36769986-B2975722-9C56-4455-B091-3115F83B36DA

P932

Q36769986-305F54E9-5E6C-4342-94DA-1A3C5DFA506A

P356

J.ANTIVIRAL.2013.01.006

P1433

Antiviral Research

P1476

Chronic hepatitis B: what should be the goal for new therapies?

@en

P2093

Anand Mehta

http://www.w3.org/2001/XMLSchema#string

Andrea Cuconati

http://www.w3.org/2001/XMLSchema#string

Haitao Guo

http://www.w3.org/2001/XMLSchema#string

Ju-Tao Guo

http://www.w3.org/2001/XMLSchema#string

Robert Gish

http://www.w3.org/2001/XMLSchema#string

Timothy M Block

http://www.w3.org/2001/XMLSchema#string

W Thomas London

http://www.w3.org/2001/XMLSchema#string

P2860

A Substituted Tetrahydro-Tetrazolo-Pyrimidine Is a Specific and Novel Inhibitor of Hepatitis B Virus Surface Antigen Secretion

Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy

Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus

Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group

Chronic hepatitis B: update 2009

Hepatitis B virus infection--natural history and clinical consequences

Genomic analysis of the host response to hepatitis B virus infection.

Clonal expansion of hepatocytes during chronic woodchuck hepatitis virus infection.

Posttranscriptional inhibition of class I major histocompatibility complex presentation on hepatocytes and lymphoid cells in chronic woodchuck hepatitis virus infection.

A multidisciplinary approach to the management of hepatocellular carcinoma.

P304

27-34

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.ANTIVIRAL.2013.01.006

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

98

http://www.w3.org/2001/XMLSchema#string

P577

2013-02-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23391846

http://www.w3.org/2001/XMLSchema#string

P932

3627746

http://www.w3.org/2001/XMLSchema#string